Modifying the cancer-immune set point using vaccinia virus expressing re-designed interleukin-2

Zuqiang Liu; Yan Ge; Haiyan Wang; Congrong Ma; Mathilde Feist; Songguang Ju; Z. Sheng Guo; David L. Bartlett

doi:10.1038/s41467-018-06954-z

Nature Communications (Nov 2018)

Modifying the cancer-immune set point using vaccinia virus expressing re-designed interleukin-2

Zuqiang Liu,
Yan Ge,
Haiyan Wang,
Congrong Ma,
Mathilde Feist,
Songguang Ju,
Z. Sheng Guo,
David L. Bartlett

Affiliations

Zuqiang Liu: Department of Surgery, University of Pittsburgh School of Medicine
Yan Ge: Department of Surgery, University of Pittsburgh School of Medicine
Haiyan Wang: Department of Surgery, University of Pittsburgh School of Medicine
Congrong Ma: Department of Surgery, University of Pittsburgh School of Medicine
Mathilde Feist: Department of Surgery, University of Pittsburgh School of Medicine
Songguang Ju: Department of Immunology, School of Biology and Basic Medical Sciences, Medical College, Soochow University
Z. Sheng Guo: Department of Surgery, University of Pittsburgh School of Medicine
David L. Bartlett: Department of Surgery, University of Pittsburgh School of Medicine

DOI: https://doi.org/10.1038/s41467-018-06954-z
Journal volume & issue: Vol. 9, no. 1
pp. 1 – 9

Abstract

Read online

IL-2 is used systemically for cancer therapy but it is associated with severe toxicity. Here, the authors design a recombinant vaccinia virus expressing membrane-bound IL-2 that shows therapeutic efficacy alone or in combination with checkpoint inhibitors in colon cancer-bearing mice.

Published in Nature Communications

ISSN: 2041-1723 (Online)
Publisher: Nature Portfolio
Country of publisher: United Kingdom
LCC subjects: Science
Website: https://www.nature.com/ncomms/

About the journal